Applied DNA Sciences, Inc. (APDN)
NASDAQ: APDN · Real-Time Price · USD
5.30
+0.25 (4.95%)
At close: Jul 8, 2025, 4:00 PM
5.30
0.00 (0.00%)
Pre-market: Jul 9, 2025, 8:04 AM EDT
Applied DNA Sciences Revenue
Applied DNA Sciences had revenue of $983.37K in the quarter ending March 31, 2025, with 5.78% growth. This brings the company's revenue in the last twelve months to $3.79M, down -31.30% year-over-year. In the fiscal year ending September 30, 2024, Applied DNA Sciences had annual revenue of $3.43M, down -74.33%.
Revenue (ttm)
$3.79M
Revenue Growth
-31.30%
P/S Ratio
0.07
Revenue / Employee
$78,971
Employees
48
Market Cap
2.76M
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Sep 30, 2024 | 3.43M | -9.94M | -74.33% |
Sep 30, 2023 | 13.37M | -4.80M | -26.43% |
Sep 30, 2022 | 18.17M | 9.14M | 101.25% |
Sep 30, 2021 | 9.03M | 7.10M | 367.40% |
Sep 30, 2020 | 1.93M | -3.46M | -64.16% |
Sep 30, 2019 | Pro | Pro | Pro |
Sep 30, 2018 | Pro | Pro | Pro |
Sep 30, 2017 | Pro | Pro | Pro |
Sep 30, 2016 | Pro | Pro | Pro |
Sep 30, 2015 | Pro | Pro | Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 410.06B |
Johnson & Johnson | 89.33B |
Merck & Co. | 63.92B |
AbbVie | 57.37B |
AstraZeneca | 54.98B |
Novartis AG | 53.22B |
Eli Lilly and Company | 49.00B |
Novo Nordisk | 43.92B |
APDN News
- 2 days ago - Applied DNA Regains Compliance with All Nasdaq Continued Listing Requirements - Accesswire
- 9 days ago - Applied DNA Sharpens Strategic Focus on Synthetic DNA Manufacturing for Biotherapeutics Applications, Consolidates Operations Behind LineaRx - Accesswire
- 21 days ago - Applied DNA Announces Retirement of Chairperson and CEO Dr. James A. Hayward - Accesswire
- 23 days ago - Applied DNA to Resume Quarterly Investor Call Cadence Beginning with FQ3'25 Financial Results Report in Mid-August - Accesswire
- 5 weeks ago - Applied DNA Announces 1-For-15 Reverse Stock Split Effective June 2, 2025 - Accesswire
- 7 weeks ago - Applied DNA Reports Second Quarter Fiscal 2025 Financial Results - Accesswire
- 7 weeks ago - Applied DNA to Announce Second Quarter Fiscal 2025 Financial Results on May 15, Schedules Intra-Quarter Investor Update Call for June 3 - Accesswire
- 2 months ago - Applied DNA's LineaRx Subsidiary Stands Ready to Support the Reshoring of Drug Development and Manufacturing with U.S.-Produced Synthetic DNA - Accesswire